Ifetroban sodium

• CAT Number: I029204
• CAS Number: 156715-37-6
• Molecular Formula: C25H31N2NaO5
• Molecular Weight: 462.51
• Purity: ≥95%
• Synonyms: sodium;3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoate
• InChI: InChI=1S/C25H32N2O5.Na/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29;/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29);/q;+1/p-1/t18-,20-,21+,23-;/m0./s1
• InChIKey: WOHSQDNIXPEQAE-QBKVZTCDSA-M
• SMILES: CCCCCNC(=O)C1=COC(=N1)[C@@H]2[C@H]3CC[C@@H]([C@@H]2CC4=CC=CC=C4CCC(=O)[O-])O3.[Na+]

Ifetroban sodium（Cat No.:I029204）is a selective antagonist of the thromboxane A2 receptor, primarily studied for its potential in treating cardiovascular diseases. By blocking the thromboxane receptor, it inhibits platelet aggregation and vasoconstriction, which are key processes in conditions such as hypertension, atherosclerosis, and thrombotic disorders. Ifetroban sodium has shown promise in reducing the risk of stroke and heart attack by improving blood flow and preventing blood clots. Ongoing clinical trials are exploring its effectiveness in various cardiovascular conditions, including its potential to treat chronic thromboembolic pulmonary hypertension (CTEPH).